Purple Biotech (NASDAQ/TASE: PPBT) is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion & drug resistancepurple-biotech.com RehovotJoined September 2016
We are thrilled to announce the initiation of the Phase 2 study for CM24 as a potential 2L treatment for patients with #PDAC, expanding the potential for treatment for #patients while extending our cash runway through 2024. More: tinyurl.com/522f8ccs#oncology#cancer#PDAC
We are pleased to share interim safety & efficacy in our Phase 1b Study of CM24 in Combination w/ Opdivo at #AACR22 saw 1 confirmed PR & 3 SD in patients with advanced pancreatic cancer and PTC. 9 patients still in study follow-up
#oncology#Cancerbit.ly/3KxZjce
Purple is excited to announce that NT219 was well-tolerated in initial clinical data from our ongoing Phase 1/2 study with a partial response observed in a patient with refractory GE junction cancer #CancerResearch#ASCO21#Curecancerbit.ly/34OKvCQ
Purple Biotech to present interim data from our ongoing Phase 1/2 clinical trial of NT219, a monotherapy for the treatment of solid tumors that has the potential to help people living with hard-to-treat cancers, on June 4 #ASCO21#cancer#cancerresearch #oncologyresearch
Happy to present new data supporting NT219's MOA, a dual inhibitor, novel SM targeting IRS1/2 & STAT3 at the Epigenetics and Metabolism AACR Virtual Conference by researchers at TASMC & Tel-Aviv University #cancer#tasmcfinance.yahoo.com/news/mechanism…
Proud to announce the U.S. commercial launch of Consensi™, designed for the simultaneous treatment of hypertension and osteoarthritis pain. Consensi™ is being sold by Burke Therapeutics, the marketing partner of our distributor, Coeptis Pharmaceuticals. tiny.cc/qjbhpz
Proud to present today our expanded planned NT-219 clinical program for difficult to treat cancers, at the 2020 Multidisciplinary Head and Neck Cancers Symposium, being held in Scottsdale, Arizona #cancer#headandneckcancer#HNCS20
Most relapses of #cancer are attributed to #drugresistance. We are developing #oncology therapies to overcome tumor drug resistance, enhance treatment response and slow tumor progression. Learn more about our pipeline: bit.ly/2LkcnW2
Proof-of-concept data showed evidence of NT-219 mechanism of action in reversing #cancer#drugresistance in PDX models. Administering NT-219 prior to chemotherapy suppressed activation of key cancer survival pathways. For more on this study, visit: bit.ly/2XT5BeU
We are developing CM-24, a clinical-stage monoclonal antibody targeting CEACAM1, a novel immune checkpoint. This #oncology therapy has the potential to treat recurrent and advanced stage #cancers. Learn more: bit.ly/37KQn0m
#TBT Check out this article in @OncoZine by our CEO, Isaac Israel, in which he shares insight on drug resistance in #cancer and a strategy for tackling the diverse cancer evolution and resistance pathways. Read more: bit.ly/37oOGW5
1K Followers 833 FollowingWe are studying human natural killer cells in viral infections and cancers in order to identify novel immune pathways to exploit for immunotherapies.
44 Followers 302 FollowingSahasra Crop Science established branded products with Sahasra for Manufacturing and Marketing of Eco-Friendly Organic fertilizer products viz. Nutraceutical.
68 Followers 479 FollowingWe support, empower, and advocate for biotech innovators.
Our mission? To develop and deliver life-saving health and wellness solutions to people worldwide.
30K Followers 13K FollowingDiscover your next Investing Idea with Stock Alerts. Podcasts, News & more 📈 AI, Biotech, Crypto, Defense, Energy, Mining & More. Read paid disclosures.
896 Followers 4K FollowingDawn Van Zant Founder & Editor of @nvestorIdeas- Navigating the Future of Investment. Host of the cleantech podcast and lead researcher for investing trends
6K Followers 50 FollowingNews affecting the biotech industry and associated stocks. Includes #biotech trends, market analysis as well as mergers and acquisition news. cc: @TheStreet
59K Followers 1K FollowingThe latest news and views about the pharmaceutical industry, with @EdSilverman of @Statnews, ex-WSJ.. tips: [email protected]
53 Followers 40 FollowingPublic Relations Associate at JV Public Relations NY, a public relations firm specializing in life sciences. http://t.co/UF6RmxlQqF
20K Followers 5K FollowingFacts matter. Truth is not liberal bias. Aw the checkmark is gone. Health/Science in plain English. Host- One World, One Health @[email protected]
2K Followers 1K FollowingFormer paperboy/journalist. Current media relations guy @ClevelandFed (views = my own). I love chess, Pearl Jam and Skyline Chili. Wapak forever. Dad of twins.
2.5M Followers 799 FollowingKnowledge is the best medicine. Providing you with trustworthy health information from the halls of @Harvardmed and world-famous affiliated hospitals.
118K Followers 2K FollowingEXPERIENCE HEALTH :: https://t.co/opL0H9CruJ :: https://t.co/kudhGuAAOH :: MEMES FROM THE HEALTH DISCORD :: https://t.co/TEialDe9og
3.7M Followers 867 FollowingPersonal Account of @DrOzCMS. Heart surgeon. Emmy Award winning TV host empowering millions to take control of their health.
1.1M Followers 118 FollowingHealth and medical news from The NYT's Health & Science desk. Sign up for the Science Times email, in your inbox every Tuesday: https://t.co/kpdN2C1hDy
12K Followers 2K Followingscience reporter @WashingtonPost, former @BostonGlobe, prefer to explore the world by bicycle, [email protected], Signal: carojo.55
2K Followers 871 FollowingHealth reporter for @TODAYshow and @NBCNews digital. I've also written about travel, business & lifestyle. Previously at CNN. Opinions are my own.